Sima Lev’s lab – Combination Therapy & Drug Resistance
Combination Therapy & Drug Resistance TNBC – Triple-Negative Breast Cancer – accounts for approximately 20 percent of all breast cancer patients and can be divided […]
Articles by Prof. Sima Lev
Treatment advances in metastatic triple-negative breast cancer (TNBC): Addressing the knowledge gap
As of February 2, 2022, 632 clinicians had completed the activity for credit. Baseline assessment data revealed gaps in knowledge regarding emerging actionable targets and […]
Researchers identify regulator of breast cancer development
Researchers identified a causative signaling pathway in breast cancer, providing potential new targets for treatment of the most common type of cancer in women. The findings […]
Accelerating AXL targeting for TNBC therapy Lohit Khera, Sima Lev
First described by electron microscopists in the early 60s the ER-Golgi contact sites in mammalian cells have remained The tyrosine kinase receptor AXL of the […]
The Golgi Apparatus and Membrane Contact Sites
First described by electron microscopists in the early 60s the ER-Golgi contact sites in mammalian cells have remained unexplored for forty years when the discovery […]
Tethering the assembly of SNARE complexes
The fusion of transport vesicles with their target mem – branes is fundamental for intracellular membrane traf – ficking and diverse physiological processes and is […]
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
Sima Lev – Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot (sima.lev@weizmann.ac.il) Targeting of estrogen receptor is commonly used as afirst-line treatment for hormone-positive […]